Abstract
Introduction
Primary and metastatic liver tumors remain an important cause of cancer-related morbidity and mortality. Surgical resection offers the best opportunity for cure in appropriately selected patients, but many patients are not surgical candidates because of tumor location, multifocal disease, limited hepatic reserve, comorbidities, or extrahepatic disease. Liver-directed therapies such as microwave ablation (MWA), chemoembolization, and radioembolization therefore play an important role in treating unresectable tumors.
Histotripsy is an emerging noninvasive, nonthermal ablation technique that uses focused ultrasound to mechanically destroy targeted tissue. Unlike conventional thermal ablation, histotripsy does not rely on heat and requires no needle or applicator placement within the tumor. These differences may provide advantages in selected patients and introduce the possibility of biologic effects beyond local tumor destruction.
Main Body
Mechanism and Potential Advantages Histotripsy delivers high-amplitude focused ultrasound pulses that generate microscopic cavitation bubble clouds within targeted tissue. Rapid expansion and collapse of these bubbles mechanically fractionate tumor tissue into acellular debris. Treatment can be targeted and monitored using real-time ultrasound.
Because tissue destruction is mechanical rather than thermal, histotripsy avoids the conventional heat-sink limitation that can reduce the effectiveness of MWA near large blood vessels. Preclinical studies have also demonstrated sharply defined treatment zones with relative preservation of collagen-rich structures such as major vessels and bile ducts. Additionally, histotripsy does not require tumor puncture, potentially avoiding complications associated with percutaneous applicator placement.
Clinical Evidence and Immunologic Effects Early human studies, including the first-in-human THERESA trial and multicenter HOPE4LIVER trial, have demonstrated the feasibility and short-term safety of histotripsy for primary and metastatic liver tumors. More recent clinical experience has shown encouraging local tumor control, although long-term survival data and randomized comparisons with established therapies remain limited.
Histotripsy may also have immunologic effects. Mechanical tumor destruction can release tumor-associated antigens and inflammatory signals without thermal denaturation. Preclinical studies have demonstrated immune-cell recruitment, tumor-specific T-cell responses, effects on untreated distant tumors, and enhanced responses when combined with immune checkpoint inhibition. These findings have raised interest in histotripsy as a potential immune primer, although this effect has not yet been established clinically.
Histotripsy also has limitations. Successful treatment requires adequate ultrasound visualization and an unobstructed acoustic window. Tumors obscured by ribs, lung, or bowel gas may be difficult to target, and long-term oncologic outcomes remain under investigation.
Conclusion
Histotripsy represents a fundamentally different approach to liver tumor ablation through noninvasive, nonthermal mechanical tissue destruction. Early clinical results demonstrate promising feasibility and safety, while avoidance of heat-sink effects and potential immune activation may provide advantages in selected patients. Histotripsy is unlikely to replace established liver-directed therapies but may expand treatment options, particularly for tumors in anatomically challenging locations. Larger comparative studies and longer follow-up are needed to establish long-term efficacy, define appropriate patient selection, and determine whether its potential immunologic effects translate into meaningful clinical benefit.